Safety and Tolerability

Incidence of adverse events similar to saline control¹

Most commonly reported treatment-emergent adverse events (≥1%) in clinical studies including randomized, double-blind, parallel-group, placebo- and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6 to 24 weeks

Incidence in which the adverse event rate is higher for ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension) than saline control.

Radiographic assessments of the knee showed no changes for most patients treated with a repeat dose of ZILRETTA at 52 Weeks²

Radiographic outcomes in patients with baseline and end-of-study radiographs (n=165)

In a real-world study on repeat administration, the median time to repeat injection was 16.6 weeks²

95.1% (195/208) of patients benefited from the first injection, and of the 195 patients,
8.2% (16/208) discontinued the trial or had no indication for the second injection

Timing of subsequent injection based on symptoms is consistent with the clinical management of OA knee pain²

– 74% of patients didn’t require a second injection for 16-24 weeks^2*

The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

*Considered to be related to progression of osteoarthritis, rather than a treatment-related change, because appearance was nonspecific and severe joint space narrowing was observed for both the baseline and end-of-study radiographs.
^†Timing of the second ZILRETTA injection among patients who received two injections (n=179): Week 12: 25.1% (45/179); Week 16: 33.5% (60/179); Week 20: 20.7% (37/179); Week 24: 20.1% (36/179). Excludes one patient who received the second injection after Week 24.

ACR=American College of Rheumatology; KOOS QOL=Knee Injury and Osteoarthritis Outcomes Score–Quality of Life; OA=osteoarthritis; TEAEs=treatment-emergent adverse events;=Western Ontario and McMaster Universities Osteoarthritis Index.

Indication and Important Safety Information

Indication

ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions

The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.

Please see full Prescribing Information.

Safety data

Incidence of adverse events similar to saline control1

Radiographic assessments of the knee showed no changes for most patients treated with a repeat dose of ZILRETTA at 52 Weeks2

In a real-world study on repeat administration, the median time to repeat injection was 16.6 weeks2

The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Incidence of adverse events similar to saline control¹

Radiographic assessments of the knee showed no changes for most patients treated with a repeat dose of ZILRETTA at 52 Weeks²

In a real-world study on repeat administration, the median time to repeat injection was 16.6 weeks²